

for studies comparing patient cohorts that have different lengths of f/u. It is particularly pertinent in the case of radiation dose escalation protocols, wherein higher dose levels are not offered until lower dose levels have been proven safe.

1393

POSTER

Analysis of the prognostic factors in germ cell tumours of the testis (GCTT)

B. Paluchowska¹, P. Wiechno², G. Madej³, P. Marczyński⁴. ¹Maria Skłodowska-Curie Memorial Cancer Center, Department of Urology-Oncology, Warsaw; ²Maria Skłodowska-Curie Memorial Cancer Center, Department of Urology-Oncology, Warsaw; ³Maria Skłodowska-Curie Memorial Cancer Center, Department of Urology-Oncology, Warsaw; ⁴Maria Skłodowska-Curie Memorial Cancer Center, Department of Urology-Oncology, Warsaw, Poland

Purpose: Analysis of the selected variables in patients (pt) with GCTT and their prognostic value for the risk of failure of the standard treatment.

Material and Methods: Nine hundred forty one pt with GCTT was treated in Maria Skłodowska-Curie Memorial Cancer Center in Warsaw from January 1980 to December 1995: 374 pt with seminoma of the testis (244 in clinical stage [CS] I, 109 in CS II, 21 in CS III) and 567 with nonseminomatous GCTT (189 in CSI, 202 in CSII, 176 in CS III). Median age was 31 years (14–83), median follow-up – 61 months (1–209) and 788/941 pt (84%) were observed longer than 2 years. Probability of survival was assessed using Kaplan-Meier method and multivariate analysis was performed using the Cox model of proportional risk. Following variables were analysed: CS, age, level of alphafetoprotein (AFP) and human chorion gonadotrophin (HCG), presence of brain, liver, bone and mediastinal metastases, number and volume of lung metastases, volume of retroperitoneal tumour, histological type.

Results: One hundred sixty four pt (17%) died. The probability of 5-year survival was 82%. The multivariate analysis revealed the following statistically significant variables: CS – $p < 0.00005$, age > 50 years – $p < 0.00005$, brain metastases – $p 0.0022$, diameter of the retroperitoneal tumour at least 10 cm – $p 0.0063$, elevated AFP – $p 0.42$, elevated HCG – $p 0.039$.

Conclusions: Clinical stage III, retroperitoneal metastatic tumour diameter at least 10 cm, presence of brain metastases, elevated AFP of HCG level, age of the patient more than 50 years are independent risk factors for the patient with GCTT.

1394

POSTER

Health-related quality of life following high dose rate brachytherapy and external beam radiation for prostate cancer

R. Galalae¹, B. Riemer¹, P. Rzehak², T. Küchler², B. Kimmig¹, G. Kovács¹. ¹Christian-Albrechts-University, Interdisciplinary Brachytherapy Centre, Kiel; ²Christian-Albrechts-University, Reference Centre Quality of Life, Department of Surgery, Kiel, Germany

Purpose: To measure the health-related quality of life (HRQoL) after combined high dose rate (HDR) 192Iridium-brachytherapy (BT) and external beam radiation (EBR) for localized prostate cancer.

Material and Methods: Hundred and eighty-nine patients were analyzed. The HRQoL of the 145 (76.7%) surviving patients at time of analysis was assessed with the core questionnaire QLQ-C30 of the EORTC and a new developed prostate-specific instrument. The reliability of both protocols was tested.

Results: The mean Cronbach's-Alpha value for the QLQ-C30 module was 0.81, and for the prostate-specific protocol 0.74, respectively. Univariate analysis of variance of the variables T-stage, grading, PSA and tumor status after therapy, and adjuvant hormonal treatment revealed that PSA elevation after radiation therapy, and adjuvant hormonal treatment were associated with significant lower level of HRQoL. T-stage and grading had no significant influence on HRQoL. In multivariate analyses only adjuvant hormonal treatment had negative impact on HRQoL without survival benefit. However, the stratification for adjuvant hormonal treatment was not according to random.

Conclusion: The HRQoL assessment with QLQ-C30 protocol and the new developed prostate-specific instrument was reliable. Survival following HDR-BT combined with EBR in men with localized prostate cancer is associated with good quality of life.

1395

POSTER

Geographic clustering of testicular cancer incidence in the northern part of The Netherlands

D.J.A. Sonneveld¹, M. Schaapveld⁴, D.Th. Sleijfer², G.J. Te Meerman³, W.T.A. Van der Graaf², R.H. Sijmons³, H. Schraffordt Koops¹, H.J. Hoekstra¹. ¹Surgical Oncology, ²Medical Oncology, ³Medical Genetics, Groningen University Hospital, Groningen; ⁴Comprehensive Cancer Centre North-Netherlands, Groningen, Netherlands

Geographic variations in testicular cancer (TC) incidence may be caused by differences in environmental factors, genetic factors, or both. In this study, geographic patterns of TC incidence rates (IRs) in the 12 provinces in The Netherlands in the period 1989–1995 were analyzed. Geographic variations within the rural North were analyzed in more detail. Incidence data were obtained from the Netherlands Cancer Registry and the Comprehensive Cancer Centre North-Netherlands. In addition, the occurrence of TC by degree of urbanisation was evaluated.

The overall annual age-adjusted IR of TC in The Netherlands between 1989–1995 was 4.4 per 100,000 men. The province Groningen in the North showed the highest annual IR with 5.8 per 100,000 men, which was significantly higher ($P < 0.05$) than the overall IR in The Netherlands (incidence rate ratio (IRR) 1.3, 95% CI 1.1–1.6). Friesland, also in the North, showed the second highest IR with 5.3 per 100,000 men (IRR 1.2, 95% CI 1.0–1.5, not significant). Analysis of IRs in 9 smaller survey areas within the 3 northern provinces Groningen, Friesland and Drenthe demonstrated 4 areas with annual IRs that were significantly higher than the IR in The Netherlands: Friesland-Southwest (IR 6.7, IRR 1.5, 95% CI 1.0–2.3), Groningen-East (IR 6.5, IRR 1.5, 95% CI 1.0–2.0), Friesland-Southeast (IR 6.1, IRR 1.4, 95% CI 1.0–1.9) and Groningen-West (IR 5.6, IRR 1.3, 95% CI 1.0–1.6). Analysis of the occurrence of TC by degree of urbanisation in The Netherlands showed no urban-rural differences by analyses of all histologic types, nor by separate analyses of the main histologic types seminomas and nonseminomas.

This study demonstrated geographic clustering of TC in the rural North of The Netherlands with some stable founder populations, which are likely to share a relatively high frequency of genes from common ancestors including possible disease related genes. Although this finding does not exclude the involvement of shared environmental factors, it may also lend support to a genetic susceptibility to TC development. TC cases in stable founder populations seem particularly suitable for searching possible disease genes predisposing to TC.

1396

POSTER

The optimal cut off value of the percentage of free PSA to enhance differentiation of prostate cancer and benign prostate disease: A prospective blind study

C.R. Yang, J.T. Chen¹, Y.Y. Horng, K.Y. Chiu, J.S. Lin, Y.L. Kao, Y.C. Ou. ¹Department of Urology, and Pathology; Taichung Veterans General Hospital, Taichung, Taiwan

Purpose: The percentage of serum free PSA (% fPSA) has been shown to improve the specificity of PSA testing for early detection of prostate cancer. However, the reported cut off value vary greatly depends on different study design, test essay and sensitivity criterion.

Methods: From Sept 1995 to Feb 1999, 476 men with serum PSA level between 4 and 25 ng/ml underwent transrectal ultrasonography (TRUS) and sextant biopsies of prostate. The age ranged from 46 to 84 with a mean age of 68.7. Just before TRUS guide biopsy, a second serum sample was obtained and stored in –70 degree freezer. The serum free and total PSA were measured with FPSA-RIACT kit and TPSA-RIACT kit (cis bio international, France).

Results: The mean % fPSA of 113 patients with prostate cancer was 18.0 ± 8.7 and was significantly ($p = 0.001$) lower than that of 363 men who were histologically benign, which mean % fPSA was 27.0 ± 10.3 . The sensitivity, specificity, and avoid biopsy rate (AVB) were shown as following table:

	Cut off value of % fPSA				
	15	20	25	30	35
Sensitivity	47.8	69.9	83.2	92.9	96.5
Specificity	91.5	79.6	60.9	34.7	19.3
AVB	82.1	67.9	50.4	28.2	15.6

If the cut off value was set on 25%, then 19 patients (17%) of cancer would be missed, and 11 of these patients were clinical significant cancer. However, using 30% fPSA as cut off could eliminate 28% negative biopsy